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Proteins to be secreted through so-called “conventional mechanisms” are characterized
by the presence of an N-terminal peptide that is a leader or signal peptide, needed
for access to the endoplasmic reticulum and the Golgi apparatus for further secretion.
However, some relevant cytosolic proteins lack of this signal peptides and should be
secreted by different unconventional or “non-canonical” processes. One form of this
unconventional secretion was named secretory autophagy (SA) because it is specifically
associated with the autophagy pathway. It is defined by ATG proteins that regulate
the biogenesis of the autophagosome, its representative organelle. The canonical
macroautophagy involves the fusion of the autophagosomes with lysosomes for content
degradation, whereas the SA pathway bypasses this degradative process to allow the
secretion. ATG5, as well as other factors involved in autophagy such as BCN1, are
also activated as part of the secretory pathway. SA has been recognized as a new
mechanism that is becoming of increasing relevance to explain the unconventional
secretion of a series of cytosolic proteins that have critical biological importance. Also,
SA may play a role in the release of aggregation-prone protein since it has been related
to the autophagosome biogenesis machinery. SA requires the autophagic pathway and
both, secretory autophagy and canonical degradative autophagy are at the same time,
integrated and highly regulated processes that interact in ultimate cross-talking molecular
mechanisms. The potential implications of alterations in SA, its cargos, pathways,
and regulation in human diseases such as metabolic/aging pathological processes
are predictable. Further research of SA as potential target of therapeutic intervention
is deserved.
Keywords: unconventional protein secretion, IL-1β, aggregate-prone proteins, macroautophagy, ATG (autophagy-
related) proteins
AUTOPHAGY
Autophagy is an evolutionarily conserved cellular process induced by nutrient starvation or lack of
growth factors that sequester and delivers cytoplasmic components to the lysosome for degradation
(1). The classical functions of autophagy are nutrient recycling functions by bulk sequestration from
the cytoplasm (2). It is also involved in the cytoplasmic component quality control by removing
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specifically damaged or aging organelles, such as depolarized
mitochondria (3). Autophagy is also important in proteostasis,
sequestering and degrading long-life proteins and invading
microbes (4). However, recent reports found that autophagy
also presents non-canonical functions (5), especially regulating
unconventional secretory processes. Thus, a novel non-
degradative role of autophagy has emerged, raising the concept
of Secretory Autophagy (SA) (6–8).
In the classical view, according to the pathway that cargo
follows to reach the lysosomal compartment, there are three
mayor types of canonical degradative autophagy. These types are:
microautophagy/endosomal microautophagy (9, 10), chaperone-
mediated autophagy (CMA) (11, 12), and macroautophagy.
The last one is characterized by the engulfment of cytoplasmic
contents by a double membrane vesicle, named autophagosome.
Therefore, macroautophagy (hereafter mentioned as autophagy)
is distinguished by the formation of the autophagosome
as its characteristic and representative intracellular
organelle (13).
The autophagic process involves the fusion of the outer
membrane of the autophagosomes with lysosomes to deliver the
inner vesicle with its cargo to the degradation compartment
forming the autolysosome. In the autolysosome, the inner
vesicle is degraded, and its products recycled. So far, more
than 100 molecules have been related to autophagy regulation
and were named ATG molecules (14). Two signaling pathways
are associated with autophagy induction: those involve mTOR
and AMPK activation. These signaling pathways can sense
the environmental, nutritional and energetic status of the
cell and promote autophagy through the ULK1-complex,
which is the first member of the core molecular machinery
in the autophagosome biogenesis [reviewed in (15, 16)]. In
brief: Following ULK1 complex activation, the transmembrane
protein VMP1 (17) recruits on the ER surface contact
site (18) where the first structure in the autophagosome
biogenesis, called omegasome, is formed. VMP1 also interacts
with the BH3 domain of BECN1 recruiting the kinase
complex PI3KC3-C1 to the autophagosome membrane (19).
The events that lead to the initial structures (isolation
membrane) are followed by the BECN1-PI3K complex activity
that phosphorylates the autophagosome membrane and two
ubiquitin-like systems ATG12 and LC3 that promote the
proper recognition of PI3P (20). In this way, cytoplasmic
ATG12 is covalently attached to a C-terminal glycine of
ATG5. Furthermore, the ATG5-ATG12 complex promotes
LC3 conjugation to phosphatidylethanolamine (PE) on the
autophagosomal membrane and this process is mediated by
ATG16L, which interacts with ATG5 to eventually form the
ATG12-ATG5-ATG16L complex [(21); Figure 1].
It is well-known that LC3 plays a central role in autophagy
being involved in vesicle elongation, maturation, fusion of
autophagosome-lysosome, and even as an adaptor to cargo
recognition (22, 23). The lipidated LC3, (LC3B) is present at the
isolation membrane and in the autophagosome, in both sides of
the membrane. The arrival of autophagosome to the lysosome,
is a fusion dependent mechanism of the HOPS complex, through
STX17 (24), and RAB7 (25). Thus, LC3 from the innermembrane
of the autophagosome is degraded with the cargo. LC3 localized
in the external membrane is cleaved from the PE by ATG4B and
then recycled (26–28).
Apart from its physiological/homeostatic function, autophagy
is also considered as a cell adaptation-to-stress process, which
frequently starts as a consequence of organelle damage caused
by oxidative species and other stress conditions. Any specific
sequestration of a selected type of cargo by autophagy for
its delivery to the lysosome is called selective autophagy (29).
Selective autophagy has a role in intracellular homeostasis,
mediating the specific degradation of cytoplasmic material
such as aggregated proteins or damaged mitochondria (30).
Interactions between autophagy receptors and ubiquitin-like
proteins constitute the molecular basis of selective autophagy.
In selective autophagy, a cargo-receptor-protein, such as
p62, makes the connection between the selected cargo and
LC3 in the autophagosomal membrane (31). Importantly,
selective degradative autophagy is involved in the cellular
response to complex diseases, such as metabolic/aging
pathological processes, by the specific degradation of
aggregation-prone or aggregated proteins (30, 32) and
organelles. These well-studied aspects of degradative autophagy
are widely considered an attractive target for therapeutic
strategies (33).
SECRETORY AUTOPHAGY
In most cases, especially in exocrine glands and neurons, proteins
are secreted by exocytosis (34). The amino-terminal signal
peptide (leader sequence) leads eukaryotic secretory proteins
into the endoplasmic reticulum (ER), following a well-defined
secretory pathway via the Golgi apparatus and eventually
progress to the cell surface through vesicular flow. However,
some relevant cytosolic proteins lack of this signal peptides
and are not able to enter the endoplasmic reticulum (ER).
Therefore, they should be secreted by different unconventional
or “non-canonical” processes that differ from the classical ER-
Golgi pathway (35–37). The autophagy machinery participates
in at least one of these pathways. Thus, as mentioned above,
this autophagy-dependent secretion pathway is also referred to
as SA (6–8).
SA is becoming of increasing relevance to explain the
secretion of a series of peptides that have critical biological
importance. Interestingly, SA has been shown to play a role
in the release of aggregation-prone proteins. This highlights
the pathophysiological relevance of this novel, but still not
fully elucidated autophagy mediated secretory pathway (38, 39).
Autophagy has been also involved in extracellular export of
cytosolic organelles, such as mitochondria that can also be
released by secretory autophagy (40). Furthermore, different
types of non-canonical autophagy have been involved in
pathogen released from infected cells (41) and associated with
the unconventionally trafficking of proteins to the plasma
membrane (42).
Interleukin-1β (IL-1β) secretion is mediated by SA. LC3B-
positive carrier sequesters IL1β from the cytosol and fuses with
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FIGURE 1 | Autophagy overview diagram flow. Autophagosome biogenesis is mediated by ULK1 activation. Here is shown that VMP1, a transmembrane protein,
recruits PI3K complex on the ER surface. Then DFCP1 recognizes the PI3P subdomain on the omegasome structure. Besides, WIPI proteins recruit the
ATG16-ATG5-ATG12 protein complex on the isolation membrane. In turn, the ATG16-ATG5-ATG12 complex mentioned above mediates LC3 lipidation on the
membrane. The genesis of the autophagosome as a double membrane vesicle allows carrying its cargo to the lysosome where the cargo is eventually degraded in the
resulting autolysosome as a final structure [reviewed in (15)]. ER, endoplasmic reticulum; PI3K, phosphatidylinositol 3-kinase; PI3P, phosphatidylinositol (3,4,5)
triphosphate (PI3P); ULK1, Unc-51-like kinase 1; VMP1, Vacuole Membrane Protein 1; DFCP1, Double FYVE-containing protein 1 (omegasome marker); WIPI,
WD40-repeat phosphoinositide-interacting protein (isolation membrane marker); LC3, Microtubule-associated proteins 1A/1B light chain 3B (vesicle maturation/cargo
recognition); ATG12, Autophagy-related protein 12 (member of ATG12-ATG5-ATG16L involved in LC3 conjugation to autophagosome membrane); ATG5,
autophagy-related protein 5; ATG16, autophagy-related protein 16.
the plasma membrane to release this cytokine through a SA
process (6–8, 43). IL-1β release seems to request the participation
of the TRIM family proteins as receptors for cargo to be secreted.
It has been reported that the TRIM family interacting with
SEC22B, as well as some Qa-SNARE (syntaxins 3 and 4), and
Qbc SNARE (SNAP 23 and 29) are needed to promote the
secretory release of IL-1β. Also, these molecules are needed for
other unconventional secretion processes, such as those involving
Lysozymes, Cathepsin A, B, C, S, Z, and other dipeptidyl-
peptidases and Tubulin (7, 44). Other SA cargos that do not
contain a signal peptide are IL-18 and HMGB1 (45, 46). SA
is not restricted to inflammasome substrates and autophagic
mediated secretion of other cytosolic proteins lacking leader
peptide have been reported, such as Galectin-3, Ferritin, and
Annexin-I (47).
It has been observed that SA is involved in α-Synuclein
aggregates associated with Parkinson’s disease (48–50). SA has
been linked to the release of aggregates of amyloid-beta (Aβ)
peptide associated with Alzheimer’s disease (46). A decrease
in Aβ secretion and extracellular Aβ plaque formation and an
increase of intracellular Aβ aggregate in the perinuclear zone
of neurons were reported in neuron-specific ATG7-deficient
mice. Also, ATG7 was able to rescue the ability to release Aβ,
whereas the induction of autophagy with rapamycin decreased
the secretion of Aβ from wild-type primary neurons (46).
Moreover, the secretion of Parkinson’s disease- and cancer-
associated protein Park7/DJ-1 is mediated by SA. Park7 secretion
is induced by autophagy through AMPK and ULK1 activation
and it is suppressed in Atg5, Atg9, or Atg16lL deficiency
animals (51). On the other hand, the inhibition of degradative
autophagy was reported to induce the unconventional secretion
of α-Synuclein and Huntingtin protein (50). Therefore,
growing evidence accumulates to point at a relevant role
of SA in pathological protein aggregate secretion and their
intracellular accumulation as mechanisms of cell response to
degenerative diseases.
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SA has a role in intestinal defense mechanisms being involved
in the secretion of Lysozyme in Paneth cells, mediated by
ATG161L (52). SA is triggered by bacteria-induced ER stress
and it is disrupted in Paneth cells of mice harboring ATG16L1,
which is a variant of ATG16L related to high risk for Crohn’s
disease. Another example is the secretion of CFTR (cystic fibrosis
transmembrane conductance regulator): knockdown of ATG5
and ATG7, and treatment with autophagy inhibitors, such as
wortmannin and 3-methyladenine, abolished the unconventional
secretion of CFTR stimulated by ER stress and an ER-to-Golgi
blockade (53).
Several ATG-proteins involved in the biogenesis of the
autophagosome have been directly related to the molecular
mechanisms in SA (Table 1). However, the participation of
the autophagosomes in the membrane trafficking pathways
of SA is not completely elucidated (37, 58). The analysis of
the mechanisms underlying unconventional protein secretion
includes a wide range of pathways that goes from different
forms of plasma membrane translocation to the generation of
extracellular vesicles (EVs).
EVs are a heterogeneous group of cell-derived membranous
structures that can be originated from the endosomal system
and micro-vesicles that are shed from the plasma membrane
(59). A type of EVs with a diameter range between 40 and
120 nm were called exosomes. It is interesting to highlight
that the secretion of exosomes was also related to the SA
pathway (60). This finding suggests that exosomes can be
another cargo for SA. Moreover, some cytoplasmic components,
from single molecules to organelles, could be involved in
the SA mechanism and may also work as SA cargos (61).
However, the intracellular membrane trafficking involved in the
exosome secretion pathway largely remains poorly understood.
In the classic view, exosome biogenesis would start when early
endosomes mature into late endosomes or MVBs (Multi Vesicle
Bodies) that fuse with the plasma membrane to release the
extracellular vesicles to the environment (62). Hence, during
this process, the endosomal membrane invaginates to generate
intraluminal vesicles (ILVs). These ILVs are finally released
into the extracellular space as exosomes, after the fusion of
MVBs with the plasma membrane. On the other hand, ATG
proteins such as ATG5, participate in exosome production (63).
The location of LC3B on the lumen side of the ILVs suggests
that a lipidation event takes place at the MVB membrane, or
membrane invaginations. Besides, the fact that intact LC3B-
positive EVs are eventually released, strongly suggests a secretory
fate of selected autophagosomes by its fusion with MVBs
in another vesicle called amphisomes (62). A recent article
provided solid evidence regarding the involvement of SA in
the EVs secretion. In this model, LC3-conjugation controlled
the formation and secretion of EVs containing RNA-binding
proteins (64). Nevertheless, the biological function of ATG5 and
other ATG proteins in exosome production and release remains
unclear (58). Finally, as it was recently reviewed, autophagy also
participates in the control of conventional secretion, including
selective types of autophagy such as such as ribophagy (65)
and zymophagy (66, 67). It acts on the secretory apparatus at
different steps, with selectivity between different secretory cell
types (68).
TABLE 1 | Examples of autophagy related molecules and modulators affecting unconventional protein secretion.
Autophagy-related molecules and
modulators
References Protein secretion Potentially affected disease
ULK1-complex (51) Park7 Parkinson’s disease
ATG5 (8, 51, 53–55) IL-1β; Park7; CFTR; IDE Parkinson’s disease; Cystic Fibrosis;
Alzheimer’s disease; several chronic
inflammatory diseases*
ATG16L1 (51, 52) Lysozyme; Park7 Parkinson’s disease; Crohn’s disease
ATG7 (50, 53, 55–57) α-synuclein; CFTR; Amyloid
beta; IDE
Parkinson’s disease; type 2 diabetes;
cystic fibrosis; Alzheimer’s disease
LC3 (8) IL-1β Several chronic inflammatory diseases*;
carcinogenesis
BECN1 (43, 55) IL-1β; IDE Alzheimer’s disease
SEC22B (7) IL-1β Several chronic inflammatory diseases*;
carcinogenesis
TRIM16 (7) IL-1β Several chronic inflammatory diseases*;
carcinogenesis
3-MA (8, 53) IL-1β; CFTR; IDE Cystic fibrosis; Alzheimer’s disease
Bafilomycin A (45, 55) IDE; IL-1β Alzheimer’s disease
Rapamycin (46) Amyloid beta Alzheimer’s disease
Spautin 1 (57) Amyloid beta Alzheimer’s disease
Starvation (8, 54) IL-1β Several chronic inflammatory diseases*;
carcinogenesis
*Including: rheumatoid arthritis, inflammatory bowel disease; autoimmune thyroiditis; type 2 diabetes.
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THE RELEVANCE OF SECRETORY
AUTOPHAGY IN DEGENERATIVE,
ENDOCRINE, AND METABOLIC DISEASE
Disease Linked With Aggregation-Prone
Proteins Deposition and Accumulation May
Be Associated With Disturbances in
Secretory Autophagy
The potential implication of alterations in autophagy
mechanisms in human health is the subject of strong research
interest. Parkinson’s disease (PD), Alzheimer’s disease (AD), and
another severe neurological diseases might be at least partially
associated with alterations in degradative autophagy and/or in
the autophagy-based secretion of certain peptides. This may
be also the case for endocrine diseases. In neurodegenerative
diseases such as PD and AD, as well as in endocrine and
metabolic disease such as Diabetes mellitus, the SA mechanism
may be altered in a way that toxic products are secreted and
accumulated outside the cell as detritus that in time can cause
cell death. In AD, Amyloid beta (Aβ) aggregates and accumulates
outside the cell causing neuron functional impairment, structural
changes and eventually cell death. The complete process reflects
a severe imbalance between production, secretion, aggregation,
and clearance of Aβ which progresses until the most advanced
stages of the disease. Some studies have shown that autophagy
plays a critical role in Aβ secretion (57, 69). Degradative
autophagy blockade is followed by Aβ intracellular accumulation
which has been demonstrated to be toxic to neurons as well
as degradative autophagy in microglia is deteriorated by long
exposure to Aβ (69). Moreover, the secretion of Aβ depends on
autophagy, since Aβ secretion and plaque formation are reduced
in mice lacking ATG7 in the excitatory forebrain neurons (57). It
has been observed that ATG7 deficient mice tend to accumulate
Aβ in the Golgi (57). Interestingly, it seems that autophagy
machinery mediates the transport of certain peptides from the
Golgi to endosomes (57). Alterations in these processes may
affect Aβ secretion and promote the intracellular accumulation
of Aβ, which in turn, results in toxic effects for cells. On the
other hand, the administration of rapamycin, an autophagy
activator, is followed by a reduction in the intracellular content
of Aβ and an improvement in cognitive function in mice (57).
Some alterations in SA have also been proposed as playing
a role in the pathophysiology of the disease. Dysfunctional
insulin-degrading enzyme (IDE), secretion may serve as an
example of these SA alterations affecting Aβ aggregation
(55). IDE -a ubiquitous enzyme of the inverzincin family of
peptidases, is involved in the clearance of insulin, insulin-like
growth factors, glucagon, amylin, and other peptides. IDE also
degrades some neurotransmitters/neurohormones, including
transforming growth factor-α, somatostatin, and endorphins.
IDE inactivates calcitonin gene-related peptide and seems
to modulate inflammatory responses, and the production of
some tumor-associated antigens (70). Cellular and oxidative
stress, insulin concentrations, free-fatty acid, and starvation
seem to modulate IDE expression. IDE dysfunction may
be associated with some forms of type 2 diabetes (T2DM),
in humans and several single nucleotide polymorphisms in
non-coding regions of the IDE gene, are associated with the
disease (71–75). However, many IDE inhibitors have resulted
in non-conclusive effects in terms of their potential as glucose
tolerance improvers (76). As this enzyme is part of the catabolic
pathways of insulin and insulin-like growth factors, high renal
and hepatic expression of IDE is not a surprise under normal
conditions. However, other cells such as astrocytes and some
neurons also display relatively high levels of IDE expression
(55). Predominantly located in the cytosol, IDE is also found
in other organelles including endosomes, peroxisomes and
mitochondria, and it is also found at the cell surface. A close to
C terminus Sly sequence motif prevents IDE from enzymatic
degradation when present at its lysosomal location (70). Usually
<10% of the enzyme is secreted, following a non-conventional
pathway. IDE secretion in microglia is enhanced by HMG-CoA
reductase inhibitors (statins) (77). Having no signal sequence,
IDE secretory pathway is mediated by autophagy. Son et al.
(55) found that simvastatin is able to induce the degradation
of extracellular Aβ40, which depended on IDE secretion from
primary astrocytes. Simvastatin increased IDE secretion is
mediated by the activation of autophagy through the LKB1-
AMPK-mTOR signaling pathway in astrocytes. Importantly,
IDE acts as a key protease for Aβ in the central nervous system.
Also, Aβ induces IDE secretion involving the contribution of
ATG genes. On the other hand, IDE secretion is associated with
GORASP (Golgi reassembly and stacking protein) physiology
(36). The dose dependent Aβ induced secretion of IDE is also
mediated by GORASP and RAB8A. Moreover, the integrity of
the autophagy flow is needed for this process. It also has been
shown that Aβ injection in mice with alterations in ATG7 results
in reduced expression and activity of IDE in the cerebrospinal
fluid potentially associated with alterations in SA (55). Even
when Aβ induced IDE secretion by astrocytes, it seems to fulfill
many of the critical characteristics required to be considered
an autophagy-mediated process. It is worth to be mentioned
that some steps in this pathway are not completely understood.
Interestingly, some epidemiological studies suggest that patients
with T2DM are at a higher risk of developing AD. However, it is
difficult to be certain about the nature of the link of both diseases
with a dysfunctional SA. A standard oral agent for the treatment
of type 2 diabetes (metformin), has shown some positive
effects in experimental models of AD. Metformin decreases
Beta-secretase 1 (BACE 1) activity which results in reduced
production of Aβ (78). The inhibition of acetylcholinesterase
(AChE) in the central nervous system, may explain at least in
part, some beneficial effects on cognitive function, learning, and
memory. Furthermore, Metformin reduces oxidative stress and
exhibits anti-inflammatory properties (78). However, metformin
is also an autophagy regulatory agent that may modulate both,
degradative and secretory autophagy, and enhance autophagic
clearance of intracellular neurofibrillary tangles formed by
hyperphosphorylated tau protein (79). The real impact of
these potential beneficial effects in clinical practice remains to
be elucidated.
Amyloid Polypeptide and other aggregation-prone proteins
accumulation surrounding the Langerhans Islet cells is a
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common finding in type 2 diabetes in humans. Islet Amyloid
Polypeptide (IAPP) accumulation is long recognized as a
phenomenon occurring in human type 2 diabetes. IAPP is co-
synthetized in beta cells and secreted along with insulin, this
is a 37-amino-acid residue polypeptide. Human IAPP forms
oligomeric structures and fibrous extracellular precipitates that
accumulate in the islets. The genetic background seems to be
associated with the degree of IAPP deposition (80) and some
nutritional factors (such as fat intake), would facilitate IAPP
deposition (81). The implications of the IAPP accumulation in
the evolution of human forms of diabetes is poorly understood.
Furthermore, extracellular human IAPP can promote autophagy
in beta cells and the reactive Oxygen Species (ROS), mediates
part of the IAPP induced degradative autophagy by involving
the AMPK pathway (82). On the other hand, it has been
suggested that intracellular IAPP oligomer formation would
be toxic for beta cells. In this way, IAPP oligomers may
damage mitochondrial membranes as well as the endoplasmic
reticulum (ER) (83). In humans, the augmented expression of
IAPP in beta cells is followed by an increase of the autophagy
flux (84). Moreover, lack of autophagy in hIAPP-expressing
animals resulted in hIAPP oligomer and amyloid accumulation
in pancreatic islets, leading to β cell death (83, 85–87). It
has been suggested that IAPP oligomers may cross plasma
membranes inducing damage by a “prion-like” effect. In this
way, the intraperitoneal injection of IAPP aggregates from the
pancreas homogenate to the transgenic mouse that expresses
hIAPP, dramatically accelerates IAPP amyloid deposition, which
was accompanied by abnormalities resembling T2DM (88, 89).
In this process, degradative autophagy integrity seems to be of
relevance. In general, increased degradative autophagy would
protect against IAPP induced damage on beta cells. However,
evidence on the potential role of SA remains less conclusive.
Alterations in IDE secretion has been suggested as part of the
pathophysiology of IAPP deposition. IAPP is a substrate of IDE.
However, IDE inhibition does not seem to increase amyloid
deposition of endogenous IAPP in vivo (90). The recently
described expression of another aggregable protein, α-synuclein,
in beta cells adds complexity to the landscape of aggregation-
prone proteins induced damage in type 2 diabetes. Alpha-
synuclein expresses in murine pancreatic islets and exogenous
overexpression of α-synuclein reduces insulin secretion by INS1
cells (91). It has been proposed that α-synuclein interacts with
the Kir6.2 subunit at the KATP channel located at the beta-
cell membrane suppressing insulin secretion (91). In normal
conditions, this mechanism may protect beta-cell from ER
stress by down-regulating exaggerated insulin secretion. In the
presence of type 2 diabetes, α-synuclein may play a negative role
in insulin release contributing to hyperglycemia, oxidative stress,
and glycosylation of protein (91). Steneberg et al. (56) showed
that autophagic flux is reduced by increased levels of α-synuclein
present in β-cells from IDE KO mice and in T2D patients. On
the other hand, Sharma et al. (92), proposed that α-synuclein is
able to activate IDE, while IDE inhibits amyloid formation by
α-synuclein. However, it is unclear if these factors may result
in increased IAPP deposition in T2DM in humans. Moreover,
several reported changes may represent indirect evidence of the
IAPP induced damage and cell adaptation. Also, these alterations
might precede or follow the intracellular accumulation of
oligomers. Finally, direct or indirect alterations in SA may result
in an increased concentration of proinflammatory mediators
such as IL-1β increasing IAPP deposition, functional alteration,
oxidative stress, and cell death.
In PD’s Disease (PD), the accumulation of α-synuclein, a
protein with high binding affinity for smaller vesicles (as synaptic
vesicles, for instance), was reported. Alpha-synuclein mutation
or over-expression impairs membrane trafficking including
exocytosis and ER-to-Golgi transport (93, 94). These alterations
are associated with ER stress, increasing oxidative stress affecting
cell homeostasis. Moreover, lysosome impairment seems to play
a critical role in the progression of the disease (95). It has
been proposed that the Secretory Carrier Membrane Protein
5 (SCAMP5), promotes the secretion of α-synuclein and other
neurotoxic proteins via exosomes (50). It has been demonstrated
that SCAMP5 has some effects as an inhibitor of degradative
autophagy, playing role in balancing several processes involved
in cell homeostasis, including vesicle trafficking as well as
constitutive, degradative and secretory autophagy (50). Also,
several other alterations linked to autophagy have been identified
in different models of PD. Alterations in the TMEM230 gene
(Transmembrane Protein 230), have been recently associated
with the pathophysiology of familial forms of the disease.
TMEM230 regulates the autophagy-mediated clearance of α-
synuclein and mediates Rab8a-associated SA. As a result, this
protein regulates Golgi-derived vesicle secretion (96). Lewy-
bodies formation, which is typically associated with cognitive
dysfunction and dementia seen in some patients with advanced
PD, may result from these alterations (96). PARK7/DJ-1
protein has been associated with PD and certain forms of
cancer. PARK7/DJ-1 participates in the regulation of several
cell processes, including anti-oxidative protection. Furthermore,
an increased pro-oxidative environment is associated with
degenerative damage along with the disease evolution. The
autophagy pathway involving ATG molecules was associated
with PARK7/DJ-1 secretion (51). Thus, impairment in autophagy
might result in the defective secretion of this protein with
potential implications in terms of anti-oxidative stress protection,
playing a role in PD progression.
Amyotrophic lateral sclerosis (ALS), is a degenerative
disorder that affects cortical, bulbar and spinal motor neurons
and is mainly characterized by a progressive adult-onset.
Like other neurodegenerative diseases, ALS is categorized
as a “proteinopathy” since SOD1, TDP-43, and FUS are
pathological proteins that accumulate, interfere, and impair
neuronal functions leading to cell death. Sproviero et al.
suggest that these toxic proteins are transported mainly by
EVs that might play a role in prion-like propagation of ALS
disease (97).
Impairment in SA May Affect the Effect and
the Concentration of Secreted Peptides
and Other Co-secreted Substances
Disruptions in SA may result in relevant changes in the
concentrations of secreted peptides and other co-secreted
molecules, as well as in their paracrine and endocrine effects.
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Altered secretion of lysozyme is related to some forms of
inflammatory bowel disease and relevant changes in host defense
mechanism. Paneth cells are specialized secretory cells in the
small intestine that have been related to Crohn disease through
a mutation of ATG16L1 (98). It has been observed, that lysozyme
and other critical secreted antibacterial proteins are rerouted
by Paneth cells through SA as a reaction to bacterial invasion.
Moreover, activation of innate lymphoid cells type 3 (ILC3)
which secrete IL22 licenses Paneth cells to secrete lysozyme
through SA (52, 99). These data suggest that Crohn disease
may be associated, at least in part, to some genetically mediated
alterations in SA.
Impaired secretion of other inflammation regulatory
molecules by a disrupted SA has been reported. IL-1β is a major
pro-inflammatory cytokine, that also doesn’t follow the classical
endoplasmic reticulum-to-Golgi route. IL-1β release is mediated
by SA requiring the participation of the microtubule-associated
protein EB1 (100). This autophagy-dependent, unconventional
secretion pathway is of special interest (45). IL-1β transcription is
induced by different stimuli ranging from microbiological agents
to other cytokines and also growth factors (101). Moreover,
neutrophils, macrophages, and microglia are relevant sources
of IL-1β under infectious and other conditions and it was
demonstrated that autophagy is responsible for IL-1β exocytosis
under these challenges. As expected for autophagy-based
secretory mechanisms, it was shown that siRNA-mediated
knockdown of ATG5 reduces IL-1β secretion in neutrophils
(54). In contrast, cell starvation increases the colocalization of
IL-1β and LC3B promoting IL-1β secretion. Extending data
including all data mentioned above strongly suggests that
SA is involved in IL-1β secretion by neutrophils and other
secreting cells.
IL-1β derives from an inactive precursor, pro- IL-1β,
that requires cleavage by caspase-1 for activation. Activation
of caspase 1 is mediated by the protein complex called
‘inflammasome’. Release of mature IL-1β relays on SA and it
has been suggested that GRASP (a Golgi apparatus associated
factor) participates in IL-1β secretion (45). After release, a
series of inhibitory molecules including IL-1Ra, sIL-1RI, sIL-
1RII, and sIL-1RAcP regulates IL-1β mediated inflammation. IL-
1β secretion has been demonstrated to be increased in several
endocrine, metabolic and degenerative conditions, as well as
some acute entities and infections. In fact, a key role in the
defense against microbial pathogens and in tissue injury repair,
is performed by IL-1β. Local and systemic responses to this
cytokine are responsible for homeostatic effects. Exaggerated
responses to IL-1β, however, are associated with potentially
deleterious effects; and excessive IL-1β activity is associated to
vasculitis and thrombosis. IL-1β also plays a role in rheumatoid
arthritis and other inflammatory diseases. Part of the structural
damage associated with PD, AD, and other degenerative entities
seems to be linked to IL-1β effects. For instance, β cells
exposure to increased concentrations of IL-1β is associated
with functional deterioration and cell death. Moreover, IL-1β
is linked to inflammation in obesity, type 2 diabetes, insulin-
resistance associated entities (e.g., polycystic ovary syndrome),
atherosclerosis and other conditions. In addition, IL-1β seems
to play a role in the pathogenesis of Autoimmune Thyroid
Diseases (102). Regarding type 2 diabetes, only when basal
levels of IL-1β mRNA are low, hyperglycemia induced IL-
1β production in β cells can be observed (103). IL-1β is
also produced by infiltrating immune cells in the pancreas
(104). Taking all this information into account, it seems
that IL-1β acts as a “metabolic sensor” aside of its well-
recognized role as pro-inflammatory mediator (105). IL-1β
physiology is a highly illustrative example of the complexities
of degradative and secretory autophagic processes. Hence, the
induction of inflammasomes triggers autophagosome formation
in macrophages (106). In some tissues, this effect may be part
of a negative mechanism to control and limit the inflammatory
response confronting challenges of infectious origin. It seems
to be also linked to an increased cytokine-mediated anti-
microbial defense.
In some cases, IL-1β was found to be increased in degradative
autophagy and may be linked to tissue damage. In pancreatic
acinar cells, IL-1β hyperactivity seems to be associated with
increased endoplasmic reticulum stress-inducing autophagy.
This mechanism may be related to an impaired autophagic flux
leading to trypsin activation and pancreatic injury. It has been
observed that Atg 5 alterations are followed by an increment in
IL-1β plasma concentration though pro-IL-1β caspase-mediated
cleavage (107). As mentioned before, autophagy is critical to
IL-1β release through the SA mechanism that involves the
AIM2 inflammasome. The interplay between different cytokines
(many of them affecting autophagy in several manners), adds
complexity to this homeostatic network. This effect may result
in a chain of autophagic process modifications affecting the SA
of regulatory peptides. Although precise mechanisms articulating
the balance between the complex processes enumerated above
remain unclear, many of them seem to be of major relevance for a
better understanding of the immune-inflammatory components
in degenerative and metabolic conditions.
Autoimmune thyroiditis (AIT) is among the main causes of
hypothyroidism in human. An increased expression of some
inflammasome components as well as IL-1β was observed in
thyroid gland tissues from AIT patients (108). This phenomenon
suggests an upregulated SA activity in these subjects and
may play a role in the pathophysiology of the disease.
Other autoimmune endocrinopathies may also reflect a certain
degree of dysfunctional SA with dysregulated secretion of IL-
1β and other cytokines. Elevated levels of pro-osteoporotic
cytokines including IL-1β have been found in patients with
different forms of hyperthyroidism (109). IL-1β secreted
by peripheral monocytes induces IL-6 secretion by stromal
cells and osteoblast, IL-6 increments osteoclast proliferation
and differentiation inducing increased bone resorption (110)
A role of IL-1β hypersecretion cannot be excluded as a
potential mediator of hyperthyroidism associated altered bone
resorption (111).
Emerging role of secretory autophagy in carcinogenesis and
endocrine tumor progression is a topic of significant clinical
relevance. Secretory autophagy may be involved in the secretion
of tumor-promoting proteins. It has been suggested, that low
expression of Rasal2 gene was associated with the recurrence of
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luminal B breast cancer (112). Recently has been shown that the
Rasal2 gene knock out induces secretory autophagy. Although
the potential mediators are not elucidated, the increase in SA
seems to be associated with luminal breast cancer proliferation
(113). Altered secretory patterns of IL-1β, IL-6, IL-8, bFGF,
and other growth factors have been demonstrated for certain
tumor types (114). Interestingly, IDE is expressed in some
human undifferentiated breast and ovarian types of cancer, as
well as in retinoblastoma. A tumor-suppressing activity was
suggested for this enzyme (115, 116). Dysfunctional SA of IDE
might play a role in very aggressive tumors. Paracrine secretion
between cancer-cell interactions would facilitate tumor initiation,
growth, and spreading. It has been suggested that paracrine
secretion of IL6, IL8, and bFGF induces autophagy in head
and neck cancer-associated fibroblasts (114). Therefore, SA and
degradative autophagy modulates critical interactions between
tumor cells and the surrounding microenvironment and may
result in significantmetabolicmodifications, with a strong impact
in cancer cell adaptations by Warburg and reverse Warburg
effects (117).
CONCLUSIONS
Macroautophagy is a complex cellular pathway characterized
by the formation of the double-membrane vesicle called
autophagosome that sequesters cytoplasmic contents to be
delivered to the lysosomal compartment for degradation.
However, increased experimental evidences strongly support
that another fate of the autophagosome biogenesis molecular
machinery exists, leading to a novel pathway of unconventional
secretion. This last process was named SA to differentiate it from
the canonical degradative autophagy (6, 61).
SA has been recognized as a novel mechanism to explain the
secretion of a series of peptides which have critical biological
importance. Although the molecular pathways and vesicular
trafficking in SA are not fully elucidated, canonical autophagy
machinery is mechanistically involved (7). Thus, the autophagy-
related proteins, such as ATG5 and several other components
of the autophagosome biogenesis (13) play a central role
in the secretion of critical disease-related proteins. Indeed,
autophagosome formation seems to be involved in the eventual
release of these relevant proteins (8). Interestingly, the fact
that cargo recognition molecules, such as the TRIM family are
mechanistically involved in this process (7) strongly suggests
that SA could be considered as a non-canonical type of selective
autophagy. In SA the process does not end in lysosomal
degradation but in the secretion of the selected cargo. A wide
range of proteins secreted bymammalian cells following different
pathways are related to autophagy and associated with human
diseases. This includes proteins related to some endocrine and
aging associated diseases.
Degradative and secretory autophagy are two integrated
multistep processes highly regulated by several physiological
and disease-related factors. Starvation, oxidative stress, and
hypoxia are well recognized stimuli for degradative autophagy.
SA efficiency depends at least in part, on the integrity of the
molecular machinery involved in the degradative processes.
Changes in degradative and secretory autophagy may result in
impairment of the release of different peptides that, in turn, may
affect autophagy in other cells by paracrine or even endocrine
ways. Implications of this interplay in the prevention, prognosis
and treatment of several diseases are still to be elucidated.
Multiple neurodegenerative disorders have in common
abnormal protein accumulation and aggregation (32).
Autophagosomes or MVBs would be able to sequester and
degrade cytosolic-protein aggregates through lysosomes.
Externalization of protein aggregates may also be mediated by
secretory autophagy. On the other hand, changes in the secretion
of protein aggregates might decrease the proteotoxic stress in the
releasing cells or reduce the spreading of protein aggregates to
neighboring cells.
There is substantial experimental data that allow us to
consider that canonical degradative autophagy and its related
factors are mechanistically associated with secretion. It has
been demonstrated that SA requires the autophagic pathway
and both, secretory and degradative autophagy are integrated
and highly regulated processes that interact in ultimate cross-
talking molecular mechanisms. Impaired secretory autophagy
may result in the aggregation-prone proteins deposition
and accumulation, or severe alterations in the release and
concentration of other secreted proteins. The relevance and
the mechanisms involved in these interactions seem to be
very important in metabolic and degenerative diseases. The
pharmacological modulation of SA and its regulatory pathways
might also be a clear target for drug research. Although there
is available evidence that outline the potential relevance of the
pharmacological control of SA, important gaps in the evidence
remain to be filled. Metformin, for instance, may modulate
SA by its demonstrated effects on degradative autophagy.
It has been observed that in patients with type 2 diabetes,
metformin upregulates mitophagy, and improves mitochondrial
function in a glucose-lowering independent manner (118). By
inhibiting macrophage activation and activating autophagic
flux, metformin reduces pro-inflammatory cytokines release
(including IL-1β) (119). However, a direct effect on SA
mechanisms cannot be excluded. Statins (HMGCoA reductase
inhibitors) increases IDE release by astrocytes in a dose-
dependent manner. These agents directly modulate SA at
least in some tissues. However, the potential relevance of
this mechanism on the beneficial and/or adverse events
associated with statin use in practice remains obscure. Iron
enhances Aβ stimulated IL-1β secretion in microglia (120).
The impact of this finding in humans is still unknown. Many
other agents seem to modulate IL-1β secretion by regulating
SA processes in different ways, and in different cell types
(121). Translation of these findings to drug development
and application into clinical practice will take a while.
However, the potential implication of impairment in secretory
autophagy, its cargos, pathways, and regulation in human
diseases such as metabolic/aging pathological processes is a
clear focus of biomedical investigation. Further research on
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secretory autophagy pathways as a potential target of therapeutic
intervention is deserved.
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